CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Go back to CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints| Boston Scientific (NYSE: BSX) | Delayed: 45.60 +1.27 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.33 | 52 Week High | $24.79 | |||
| Open | $44.63 | 52 Week Low | $15.67 | |||
| Day High | $45.69 | P/E | N/A | |||
| Day Low | $44.40 | EPS | $-0.09 | |||
| Volume | 18,683,515 | |||||
